Navigation Links
JNCI news brief: Melanosome dynamics and sensitivity of melanoma cells to chemotherapy
Date:8/24/2009

Manipulating the functions of melanosomes--the organelles in pigment-producing cells--may enhance the activity of anticancer drugs used against melanoma, according to a new study published online August 24 in the Journal of the National Cancer Institute.

To examine the role of melanosomes in the sensitivity of malignant melanoma to chemotherapeutic agents, Kevin Chen, Ph.D., Vincent Hearing, Ph.D., Michael M. Gottesman, M.D., of the Laboratory of Cell Biology at the National Cancer Institute in Bethesda, Md., and colleagues compared pigmentation and melanosome developmental stage, number, and cellular structures in melanoma cell lines in response to treatment with chemotherapeutic agents.

The authors found that late-stage melanosomes that were damaged and thus could not trap metabolites were toxic to melanoma cells. They also found that melanoma cells that survived cisplatin treatment had more stage II-III functional melanosomesalso known as early melansomes because they have not initiated melanin synthesisthan untreated melanoma cells. In addition, when melanosomes were reverted to relatively early stages, the melanoma cells became more resistant to cisplatin.

"We believe that manipulation of melanosome status either by cytotoxic or by noncytotoxic drugs opens therapeutic avenues and raises the prospect of successfully treating pigment-producing cell-related diseases and, in particular, highly intractable malignant melanomas," the authors write.


'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Page: 1

Related medicine news :

1. JNCI news brief: Surgeon training found effective in breast cancer sentinel lymph node trial
2. JNCI news brief: High serum insulin levels and risk of prostate cancer
3. JNCI news brief: Antibody linked to chemotherapy drug inhibits ovarian cancer in lab
4. JNCI news brief: Breast cancer hormone receptor status and risk of a second primary tumor
5. JNCI news brief: Hepatitis B virus mutations may predict risk of liver cancer
6. JNCI news brief: Improving the biomarker pipeline for early cancer detection
7. In brief: New prognostic indicator for patients with IPF
8. MicroDynamics to Introduce New Microscope at Quality Expo
9. CardioDynamics Shareholders Approve Merger Agreement with SonoSite
10. CardioDynamics Reports Second Fiscal Quarter 2009 Results
11. General Dynamics Awarded $9 Million Contract for U.S. Army Medical Command Lean Six Sigma Support
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
Breaking Medicine Technology: